Introduction: Patients who need tricuspid valve replacement (TVR) surgery often have permanent transvalvular pacemaker (PM) leads, which pose an important challenge in lead management.
Aim: The objective of this study was to evaluate the results of paravalvular positioning of a permanent pacemaker lead during TVR surgery.
Material And Methods: Between 2014 and 2024, a total of 15 patients who had previously had a transvenous pacemaker system underwent TVR. Relevant information, with a focus on pacemaker characteristics, was collected retrospectively.
Results: A total of 15 patients with PM lead previously implanted underwent TVR during the study period. The median time interval between pacemaker implantation and TVR was 8.5 years (5.7-10.5 years). The preoperative median threshold amplitude and impedance values were 1 V (0.68-1.25 V) and 518 Ω (377.5-598.7 Ω), whereas the postoperative median threshold amplitude and impedance values were 0.73 V (0.5-1 V) and 460 Ω (378.5-550). During the midterm follow-up, there were no mortalities or significant morbidities, and no patients required pacemaker lead revision.
Conclusions: We concluded that paravalvular positioning of the PM lead is an acceptable option during TVR surgery, since this technique enables better function of the prosthetic valve and pacemakers at mid-term follow-up.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704753 | PMC |
| http://dx.doi.org/10.5114/kitp.2024.145836 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Paravalvular positioning of a cardiac implantable electronic device electrode during tricuspid valve replacement.
Kardiochir Torakochirurgia Pol
December 2024
Department of Cardiovascular Surgery, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Introduction: Patients who need tricuspid valve replacement (TVR) surgery often have permanent transvalvular pacemaker (PM) leads, which pose an important challenge in lead management.
Aim: The objective of this study was to evaluate the results of paravalvular positioning of a permanent pacemaker lead during TVR surgery.
Material And Methods: Between 2014 and 2024, a total of 15 patients who had previously had a transvenous pacemaker system underwent TVR.
Computational evaluation of interactive dynamics for a full transcatheter aortic valve device in a patient-specific aortic root.
Comput Biol Med
December 2024
Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Epinal Way, Loughborough, LE11 3TU, UK. Electronic address:
Transcatheter aortic valve implantation (TAVI) has become a key treatment for severe aortic stenosis, especially for patients unsuitable for surgery. Since its introduction in 2002, TAVI has advanced significantly due to improvements in imaging, operator skills, and device engineering. Despite these innovations, challenges in device sizing and positioning remain, complicating outcome predictions.
View Article and Find Full Text PDFTranscatheter Mitral Valve Replacement Using Annular Reduction by Cinching With TEER in the Commissure (ARCTIC).
Circ Cardiovasc Interv
November 2024
Department of Cardiology (G.J.C., D.E., C.S., C.J.C., J.M.M.), University of Washington School of Medicine, Seattle.
Background: Mitral annular calcification with valve dysfunction remains a challenging syndrome. Operative risk is high, and available transcatheter therapies are limited.
Methods: This study describes our initial experience with a novel procedure to address large mitral annuli when no surgical or trial-based transcatheter mitral valve replacement device is available.
The novel balloon-expandable Myval transcatheter heart valve: systematic review of aortic, mitral, tricuspid and pulmonary indications.
Rev Esp Cardiol (Engl Ed)
October 2024
Servicio de Cardiología, Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario, Valladolid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. Electronic address:
Article Synopsis
- Myval technology is a new balloon-expandable option for treating heart valve issues, emerging after the established Edwards system, and its usage is increasing despite some debated points.
- A thorough literature review covering studies from December 2016 to May 2024 showed Myval to be effective for native aortic stenosis with low mortality and complication rates, and its performance compares favorably to other devices.
- The findings also indicate that Myval is safe for various off-label uses, achieving high success rates across different heart valve procedures, although more extensive studies are needed to confirm these results.
A new simple technique for stabilizing the guidewire position within the left ventricle during transcatheter mitral valve-in-valve implantation.
Catheter Cardiovasc Interv
November 2024
Department of Pediatric Cardiology, Institute of Cardio Vascular Diseases, Madras Medical Mission, Chennai, India.
Transcatheter mitral valve-in-valve implantation is a preferred treatment for degenerating mitral bioprosthetic valves in high-risk surgical patients. A balloon-expandable transcatheter heart valve delivered through a postero-inferior transseptal puncture is deployed within the prosthesis over a guidewire secured in the left ventricle. Patients with aneurysmal left atrium and altered angulation between the planes of atrial septum and mitral prosthesis have unstable position of the guidewire that flips out of the left ventricle into the left atrium when the valve delivery system is advanced.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!